Solugen is moving its HQ into Phoenix Tower. Photo courtesy of Parkway

Houston-based Solugen has announced an HQ move. But don't worry. This unicorn chemicals company is just moving down the street.

Parkway Property Investments LLC announced today that Solugen is relocating its Houston corporate headquarters to Greenway Plaza. The biotech company, recently ranked as one of the most innovative businesses in the world, signed a multi-year lease in Phoenix Tower. The building is one of 11 Class A buildings on the 52-acre mixed-use campus.

The space's buildout is expected to be completed in the second quarter, according to a news release, with Solugen moving in after that.

The venture-backed biotech startup, which produces high-performance chemicals through the use of bio-based feedstock and metal catalyst technologies, signed a multi-year lease in Phoenix Tower. The property is one of eleven Class A buildings on the landmark, 52-acre mixed-use campus, which is strategically located between Downtown and Uptown. Buildout of the space is expected to be completed in the second quarter.

“Innovative companies like Solugen are choosing to outsource the design-build process for office interiors to Parkway," says Eric Siegrist, Parkway’s managing director of leasing, in the release. "With several floors of ‘Ready Right Away’ suites fully-deployed, we happily take on this process to reduce the time and energy expended by an incoming tenant, resulting in expedited occupancy.”

Solugen was represented by Nick Terry, managing partner of Rifle Real Estate. Parkway’s senior director of leasing, JP Hutcheson, negotiated on behalf of Parkway.

Founded in 2016, Solugen’s process converts corn syrup into industrial chemicals, cutting down on carbon emissions generated by traditional production of chemicals. Carbon dioxide from chemical production is one of the biggest contributors to industrial greenhouse gas emissions. In September, the company raised a $357 million series C funding round and claimed its unicorn status.

Solugen joins several tech companies already housed in Greenway Plaza, including FlightAware, ThoughtTrace, Detechtion Technologies, and Buildforce.

Phoenix Tower has 627,320 square feet of space across 34 floors. Photo courtesy of Parkway


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.